A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

Robert S. Sandler, Susan Halabi, John A. Baron, Susan Budinger, Electra Paskett, Roger Keresztes, Nicholas Petrelli, J. Marc Pipas, Daniel D. Karp, Charles Lawrence Loprinzi, Gideon Steinbach, Richard Schilsky

Research output: Contribution to journalArticle

930 Citations (Scopus)

Abstract

BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers. METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations. Relative risks were adjusted for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy. The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis. RESULTS: A total of 517 randomized patients had at least one colonoscopic examination a median of 12.8 months after randomization. One or more adenomas were found in 17 percent of patients in the aspirin group and 27 percent of patients in the placebo group (P= 0.004). The mean (±SD) number of adenomas was lower in the aspirin group than the placebo group (0.30±0.87 vs. 0.49±0.99, P=0.003 by the Wilcoxon test). The adjusted relative risk of any recurrent adenoma in the aspirin group, as compared with the placebo group, was 0.65 (95 percent confidence interval, 0.46 to 0.91). The time to the detection of a first adenoma was longer in the aspirin group than in the placebo group (hazard ratio for the detection of a new polyp, 0.64; 95 percent confidence interval, 0.43 to 0.94; P=0.022). CONCLUSIONS: Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.

Original languageEnglish (US)
Pages (from-to)883-890
Number of pages8
JournalNew England Journal of Medicine
Volume348
Issue number10
DOIs
StatePublished - Mar 6 2003

Fingerprint

Adenoma
Aspirin
Colorectal Neoplasms
Placebos
Random Allocation
Clinical Trials Data Monitoring Committees
Confidence Intervals
Incidence
Colonoscopy
Polyps
Observational Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., ... Schilsky, R. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New England Journal of Medicine, 348(10), 883-890. https://doi.org/10.1056/NEJMoa021633

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. / Sandler, Robert S.; Halabi, Susan; Baron, John A.; Budinger, Susan; Paskett, Electra; Keresztes, Roger; Petrelli, Nicholas; Pipas, J. Marc; Karp, Daniel D.; Loprinzi, Charles Lawrence; Steinbach, Gideon; Schilsky, Richard.

In: New England Journal of Medicine, Vol. 348, No. 10, 06.03.2003, p. 883-890.

Research output: Contribution to journalArticle

Sandler, RS, Halabi, S, Baron, JA, Budinger, S, Paskett, E, Keresztes, R, Petrelli, N, Pipas, JM, Karp, DD, Loprinzi, CL, Steinbach, G & Schilsky, R 2003, 'A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer', New England Journal of Medicine, vol. 348, no. 10, pp. 883-890. https://doi.org/10.1056/NEJMoa021633
Sandler, Robert S. ; Halabi, Susan ; Baron, John A. ; Budinger, Susan ; Paskett, Electra ; Keresztes, Roger ; Petrelli, Nicholas ; Pipas, J. Marc ; Karp, Daniel D. ; Loprinzi, Charles Lawrence ; Steinbach, Gideon ; Schilsky, Richard. / A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. In: New England Journal of Medicine. 2003 ; Vol. 348, No. 10. pp. 883-890.
@article{6a51ad287d284f3b94ee6e3403fdbed4,
title = "A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer",
abstract = "BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers. METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations. Relative risks were adjusted for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy. The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis. RESULTS: A total of 517 randomized patients had at least one colonoscopic examination a median of 12.8 months after randomization. One or more adenomas were found in 17 percent of patients in the aspirin group and 27 percent of patients in the placebo group (P= 0.004). The mean (±SD) number of adenomas was lower in the aspirin group than the placebo group (0.30±0.87 vs. 0.49±0.99, P=0.003 by the Wilcoxon test). The adjusted relative risk of any recurrent adenoma in the aspirin group, as compared with the placebo group, was 0.65 (95 percent confidence interval, 0.46 to 0.91). The time to the detection of a first adenoma was longer in the aspirin group than in the placebo group (hazard ratio for the detection of a new polyp, 0.64; 95 percent confidence interval, 0.43 to 0.94; P=0.022). CONCLUSIONS: Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.",
author = "Sandler, {Robert S.} and Susan Halabi and Baron, {John A.} and Susan Budinger and Electra Paskett and Roger Keresztes and Nicholas Petrelli and Pipas, {J. Marc} and Karp, {Daniel D.} and Loprinzi, {Charles Lawrence} and Gideon Steinbach and Richard Schilsky",
year = "2003",
month = "3",
day = "6",
doi = "10.1056/NEJMoa021633",
language = "English (US)",
volume = "348",
pages = "883--890",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

AU - Sandler, Robert S.

AU - Halabi, Susan

AU - Baron, John A.

AU - Budinger, Susan

AU - Paskett, Electra

AU - Keresztes, Roger

AU - Petrelli, Nicholas

AU - Pipas, J. Marc

AU - Karp, Daniel D.

AU - Loprinzi, Charles Lawrence

AU - Steinbach, Gideon

AU - Schilsky, Richard

PY - 2003/3/6

Y1 - 2003/3/6

N2 - BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers. METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations. Relative risks were adjusted for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy. The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis. RESULTS: A total of 517 randomized patients had at least one colonoscopic examination a median of 12.8 months after randomization. One or more adenomas were found in 17 percent of patients in the aspirin group and 27 percent of patients in the placebo group (P= 0.004). The mean (±SD) number of adenomas was lower in the aspirin group than the placebo group (0.30±0.87 vs. 0.49±0.99, P=0.003 by the Wilcoxon test). The adjusted relative risk of any recurrent adenoma in the aspirin group, as compared with the placebo group, was 0.65 (95 percent confidence interval, 0.46 to 0.91). The time to the detection of a first adenoma was longer in the aspirin group than in the placebo group (hazard ratio for the detection of a new polyp, 0.64; 95 percent confidence interval, 0.43 to 0.94; P=0.022). CONCLUSIONS: Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.

AB - BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers. METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations. Relative risks were adjusted for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy. The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis. RESULTS: A total of 517 randomized patients had at least one colonoscopic examination a median of 12.8 months after randomization. One or more adenomas were found in 17 percent of patients in the aspirin group and 27 percent of patients in the placebo group (P= 0.004). The mean (±SD) number of adenomas was lower in the aspirin group than the placebo group (0.30±0.87 vs. 0.49±0.99, P=0.003 by the Wilcoxon test). The adjusted relative risk of any recurrent adenoma in the aspirin group, as compared with the placebo group, was 0.65 (95 percent confidence interval, 0.46 to 0.91). The time to the detection of a first adenoma was longer in the aspirin group than in the placebo group (hazard ratio for the detection of a new polyp, 0.64; 95 percent confidence interval, 0.43 to 0.94; P=0.022). CONCLUSIONS: Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037421984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037421984&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa021633

DO - 10.1056/NEJMoa021633

M3 - Article

C2 - 12621132

AN - SCOPUS:0037421984

VL - 348

SP - 883

EP - 890

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 10

ER -